Fetal hemoglobin

Fetal hemoglobin. It is the primary oxygen-carrying protein in the developing human fetus, exhibiting a higher affinity for oxygen than adult hemoglobin. This hemoglobin variant is composed of two alpha globin and two gamma globin chains, a structure encoded by the HBG1 and HBG2 genes on chromosome 11. Its unique biochemical properties are crucial for efficient oxygen transfer across the placenta from maternal blood to fetal circulation.

Structure and genetics

Fetal hemoglobin possesses a tetrameric structure consisting of two alpha globin chains and two gamma globin chains, denoted as α₂γ₂. The gamma globin chains are the products of two nearly identical genes, HBG1 and HBG2, located in the beta-globin gene cluster on the short arm of chromosome 11. This locus also houses the genes for adult hemoglobin beta globin and delta globin. A key structural difference from adult hemoglobin lies in the gamma globin chains, which contain specific amino acid substitutions that reduce binding to 2,3-bisphosphoglycerate. This alteration is fundamental to its increased oxygen affinity. The production of alpha globin is directed by genes on chromosome 16, which are shared with adult hemoglobin variants.

Function and physiological role

The primary function of fetal hemoglobin is to facilitate oxygen transport in the fetal circulatory system. Its higher oxygen affinity, relative to maternal adult hemoglobin, creates an efficient gradient for oxygen transfer across the placenta. This is largely due to diminished interaction with 2,3-bisphosphoglycerate, a molecule that normally decreases oxygen affinity in red blood cells. Consequently, fetal blood can become highly oxygenated even at the lower oxygen partial pressures found in the umbilical vein. This adaptation ensures adequate oxygen delivery to developing fetal tissues, including the brain and heart, supporting metabolism and growth during gestation.

Developmental regulation and switching

Expression of fetal hemoglobin is developmentally regulated through a process known as the hemoglobin switch. During fetal development, hematopoiesis occurs primarily in the liver and spleen, producing red blood cells rich in fetal hemoglobin. Around the time of birth, a transcriptional shift occurs, silencing the gamma globin genes and activating the beta globin gene. This switch coincides with the relocation of major hematopoiesis to the bone marrow. The process is orchestrated by complex interactions involving transcription factors like BCL11A and KLF1, as well as the locus control region of the beta-globin gene cluster. By approximately six months of age, fetal hemoglobin levels typically decline to less than 1% of total hemoglobin in most individuals.

Clinical significance

Fetal hemoglobin has profound clinical importance, particularly in the context of hemoglobinopathies. In patients with sickle cell disease or beta thalassemia, elevated levels of fetal hemoglobin can ameliorate disease severity. This is because gamma globin chains can dilute the pathological sickle hemoglobin or compensate for deficient beta globin production. The hereditary persistence of fetal hemoglobin is a benign condition caused by mutations in the beta-globin gene cluster, such as deletions in the HBG1 and HBG2 promoters. Furthermore, fetal hemoglobin is a key diagnostic marker in certain leukemias, and its presence can be used to monitor treatment response following procedures like bone marrow transplantation.

Research and therapeutic applications

Substantial research focuses on reactivating fetal hemoglobin expression as a therapeutic strategy for sickle cell disease and beta thalassemia. Approaches include pharmacologic agents like hydroxyurea, which can modestly increase fetal hemoglobin levels. More targeted strategies involve gene therapy and gene editing technologies, such as CRISPR-Cas9, to disrupt repressive elements like the BCL11A gene or its enhancer regions. Clinical trials, including those sponsored by the National Institutes of Health and companies like Vertex Pharmaceuticals and CRISPR Therapeutics, have shown promising results. Ongoing investigations also explore the role of the HBB locus and other modifiers in fine-tuning gamma globin gene expression for optimal therapeutic outcomes.

Category:Proteins Category:Hemoglobin Category:Human development